Relapse after allogeneic progenitor cell transplant is associated with a poor prognosis for patients with advanced leukemia, with few curative options available. Use of novel chemotherapeutic agents with limited toxicity is warranted. We investigated the role of decitabine, a pyrimidine analogue with significant anti-leukemic effect and limited toxicity, in this setting. Fourteen patients with advanced acute leukemia or transformed chronic myelogenous leukemia (CML) who had failed previous allogeneic transplant were treated. Decitabine at doses of 100 mg/m 2 to 150 mg/m 2 given every 12 h for 5 days was followed by infusion of stem cells from the original donor 2 to 5 days after the completion of chemotherapy. Dose of decitabine was escalated in cohorts of three patients based on the modified Fibonacci scheme. The primary study end-point was assessment of the toxicity of the regimen with secondary endpoints of response and survival. Eight patients responded with either a complete remission or partial hematological remission (absence of blasts in peripheral blood and bone marrow but with platelet count Ͻ100 × 10 9 /l). Toxicity was limited with no grade 3 or 4 toxicity directly attributable to the treatment. The median survival for all patients was 190 days (range 11 to 1215+ days). Decitabine at doses of 100 mg/m 2 to 150 mg/m 2 given every 12 h for 5 days, followed by stem cell infusion from the original donor was well tolerated, and was associated with acceptable myelosuppression. Current response data should encourage further study of this drug, either alone or in combination with other agents, for treatment of relapsed acute leukemia after an allogeneic transplant. Bone Marrow Transplantation (2001) 27, 1221-1225.
Despite significant advances in the understanding and treatment of leukemias over the past decade, the majority of patients with transformed CML and advanced acute leukemia cannot be cured. Allogeneic stem cell transplantation used as consolidation therapy, or for the treatment of relapsed disease, has the potential to cure some patients, but is associated with a high relapse rate. 1 Available options for treatment of relapse following allogeneic transplant are limited and include donor lymphocyte infusion (DLI), investigational and conventional salvage regimens, and a second transplant. 2 Conventional chemotherapy regimens achieve complete remissions in a minority of patients and are rarely durable. [1] [2] [3] Intensifying novel therapeutic agents for treatment of relapse after an allogeneic transplant may improve results.
Methylation of CpG dinucleotide islands in human DNA, as maintained by the enzyme cytosine DNA methyltransferase, has been the subject of intensive research. 4 Hypermethylation of promoter regions has emerged as an important mechanism of suppression of several genes including the calcitonin gene, p16, p15, Igf-2, c-abl and others, putatively involved in the control of growth of leukemic cells. 4 The inhibition of the enzyme DNA methyltransferase is associated with hypomethylation, and reactivation of such tumor suppressor genes. 4 Decitabine (5-aza-2′-deoxycitidine; DAC) is a pyrimidine analogue, initially synthesized in 1964. 5 Its anti-leukemic potential was first realized by Sorm and Vesely in 1968 . 6 Recent studies have demonstrated that the anti-leukemic activity of decitabine, and its analogue 5-azacytidine, may be related to their ability to inhibit DNA methyltransferase by forming covalent adducts with the enzyme. 7, 8 The activation of silent genes is believed to be responsible for the induction of terminal differentiation of the leukemic cells leading to senescence and apoptosis. 7, 9, 10 Laboratory studies, carried out on the peripheral blood and bone marrow cells of patients treated with decitabine has revealed phenotypic modification of the leukemic cells, with the reduction of expression of CD13 and CD33 and an increase in antigenic density of surface determinants of mature myeloid cells such as CD16 and CD11c. 11, 12 Of interest, the expression of MHC class I molecules, HLA-DR and beta-2-microglobulin on the surface of leukemic cells is markedly increased during decitabine therapy. 12 Therefore, decitabine treatment may increase the efficacy of an immune-mediated therapy such as IL-2 or the graft-versusleukemia effect associated with transplantation or donor lymphocyte infusions. 7, 13 Several phase I and II studies have demonstrated the efficacy of decitabine in achieving responses in patients with relapsed or refractory leukemia. [14] [15] [16] Of particular interest is the limited extramedullary toxicity associated with decitabine, with myelosuppression being the major drug-related toxicity. 15 However, in patients starting therapy with an absolute neutrophil count of у0.5 × 10 9 /l an aplastic phase is unusual. [14] [15] [16] Here, we report the results of a phase I study of single agent decitabine with stem cell re-infusion for relapse after allogeneic progenitor cell transplant.
Patients and methods

Eligibility criteria
Patients with acute leukemia, myelodysplastic syndrome or chronic myelogenous leukemia (CML) in accelerated or blast phases who had relapsed after allogeneic bone marrow or stem cell transplantation were eligible to enter the study. Eligibility criteria were: age Ͻ60, adequate renal, liver and cardiac function with a serum bilirubin р3 mg/dl, serum creatinine р2 mg/dl, and a left ventricular ejection fraction у40%, respectively, absence of an active uncontrolled infection, performance status of р3, absence of active graft-versus-host disease (GVHD) уgrade 2 or extensive chronic GVHD, absence of pregnancy, active neurologic disease or serious inter-current illness. The protocol was approved by the Institutional Review Board; patients signed a written informed consent prior to the initiation of treatment.
Treatment plan
All patients had relapsed following an allogeneic transplant from an HLA-matched sibling. In the initial transplant all patient had received un-manipulated stem cells except for one patient who had received a CD8-depleted graft. Decitabine at a dose of 100 mg/m 2 was administered intravenously as a 6 h infusion every 12 h for 5 days (total dose 1000 mg/m 2 ) followed by infusion of unmanipulated stem cells from the original donor 2 days after the last dose of decitabine . Two of the first three patients treated required additional donor stem cells because of lack of engraftment by day 21. This resulted in the subsequent modification of the regimen with infusion of donor stem cells 5 days after the last dose of decitabine. The 5 day delay was intended to allow for clearance of any unidentified active metabolite of decitabine which could affect the engraftment kinetics. Patients received GVHD prophylaxis with intravenous cyclosporine or FK506 (Tacrolimus) beginning on day −2, and converted to oral dosing as soon as tolerated. Cyclosporine and FK506 doses were adjusted according to the measured blood levels, to achieve target levels of 150 to 250 ng/ml, and 5 to 15 ng/ml, respectively. Solumedrol was administered at a dose of 0.5 mg/kg starting on day 5 followed by a rapid taper of the drug. Cyclosporine dose was tapered by 20% weekly starting on day 50 and the dose of FK506 was gradually tapered based on clinical assessment.
Collection of the stem cells was performed using the standard techniques with G-CSF priming starting 2-4 days prior to the first collection followed by leukopheresis performed daily until Ͼ4 × 10 6 CD34 + cells/kg were collected. Patients received prophylactic antibiotic therapy against Pneumocystis carinii, cytomegalovirus, bacterial and fungal infections according to current standard regimens. Filtered and irradiated blood products were used to maintain the hemoglobin above 8.5 g/dl and platelet count above 20 × 10 9 /l.
Study endpoints and statistical considerations
Engraftment was defined as the first of 3 consecutive days with a neutrophil count of greater than 0.5 × 10 9 /l. Criteria for response to therapy were defined as follows: Complete remission was defined as having a normocellular bone marrow with р5% blast cells, normal peripheral counts with a granulocyte count of Ͼ1.0 × 10 9 /l and platelet count of Ͼ100 × 10 9 /l, and with reconstitution of donor hemopoiesis documented by cytogenetics or by restriction fragment length polymorphism (RFLP). Remission with partial hematologic recovery was defined as the presence of the above criteria with the exception of a platelet count of Ͻ100 × 10 9 /l. Hematologic remission with mixed chimerism was defined as the above with persistence of residual host hematopoiesis as identified by cytogenetics or RFLP. Toxicity was scored using Bearman's criteria. 17 Acute and chronic GVHD were scored as previously reported. 18, 19 The dose of decitabine was escalated in the absence of extramedullary toxicity of grade 3 or worse and absence of engraftment failure. Cohorts of three patients were entered at each dose level: if grade 3 extramedullary toxicity or failure of engraftment was encountered three more patients were entered at the same dose level. Incidence of extramedullary toxicity of grade 3 or greater in у two patients at any dose level was indicative of that level being the level above the maximum tolerated dose (MTD).
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Fourteen patients with a median age of 35 years (range 22 to 50 years) have been treated. Nine patients had acute myeloid leukemia (AML), two had acute lymphoblastic leukemia (ALL), and three had accelerated/blastic phase CML. The median time from previous transplant was 177 days (range 49 to 540 days). At the time of enrollment, all but two patients had active disease, and nine of 10 patients had failed withdrawal of immunosuppression with or without G-CSF. Two patients had failed salvage chemotherapy, and two had failed DLI. Table 2 summarizes patient and disease characteristics at the time of decitabine therapy. The features of the first transplant are summarized in Table 3 .
Engraftment and response
Eight patients achieved either a complete remission, or a remission with partial hematologic recovery. In three of these patients this was achieved following a subsequent DLI. The median time to neutrophil recovery for these Bone marrow 4 Peripheral blood 10 CP = chronic phase; AP = accelerated phase; CR = complete remission; TBI = total body irradiation; CsA = cyclosporine; MP = methylprednisone.
responding patients was 13 days (range 10 to 30 days). Seven of the eight patients achieving response became independent of platelet transfusions at a median of 22 days (range 15 to 29) post transplant. Two of the first three patients treated required additional donor stem cells because of lack of engraftment by day 21. Subsequent modification of the regimen with infusion of donor stem cells 5 days after the last dose of decitabine alleviated the problem with all subsequent patients except one achieving an absolute neutrophil count у0.2 × 10 9 /l within 2 weeks. In one patient this was achieved in 28 days.
Toxicity
No Bearman grade 3 or 4 toxicity directly attributable to the treatment was noted. Two patients had grade 2 liver toxicity (in 1 associated with GVHD), and one patient had grade 2 gastrointestinal toxicity with nausea and mucositis. Grade 3 central nervous system toxicity was observed in one patient, believed to be related to sepsis and cyclosporine therapy. Ten patients had no significant toxicity attributable to the regimen. Acute GVHD у grade 2 was seen in four patients. The toxicities encountered are summarized in Table 4 . Table 4 Toxicity 
Survival
Seven of eight patients achieving a response have relapsed and one patient died in hematologic remission from infections. Two patients are in CR having achieved it after a further DLI. The median survival for all patients was 190 days (range 11 to 1245+ days). The median disease-free survival for the patients achieving a response was 60 days (range 29 to 368+ days). Overall, five patients are alive 176+ to 1245+ days post transplant: two in remission, two with refractory disease, and one after receiving another allogeneic transplant from an alternate donor (Table 5) . Six patients died from progressive disease, two from infection, and one from GVHD and associated infections (Figure 1 ).
Discussion
Relapse remains the most important cause of treatment failure among patients receiving allogeneic progenitor cell transplant with advanced leukemia [1] [2] [3] Available options for patients relapsing after an allogeneic transplant include DLI, a second transplant, or investigational salvage therapies. 1, 2, 20, 21 Patients relapsing within 12 months of transplant have a poor outcome, with a less than 20% responding to chemotherapy, and rare long-term survivors. [1] [2] [3] The role of conventional transplants in this setting is limited, as they can only be performed in young patients with a good performance status and a long initial remission following first transplant. 21 Donor lymphocyte infusions have a 20% to 30% likelihood of achieving a response, but are associated with short remissions and attendant toxicities. 20 New therapeutic strategies in this setting are warranted.
In this study, we have demonstrated the feasibility of treating patients with relapsed leukemia following an allogeneic transplant using decitabine with allogeneic progenitor cell support. The regimen was associated with little toxicity and could be administered to patients who, as a result of their disease or prior therapies, have worse performance status. It was effective in achieving remissions in a significant number of patients. Of interest, long-term remissions were all achieved after DLI in patients who were in partial remission or in remission with mixed chimerism, leading to the speculation that the regimen can enhance the effect of DLI possibly through enhanced expression of co-stimulatory molecules or differentiation antigens.
We conclude that decitabine at doses of up to 1500 mg/m 2 is well-tolerated in patients with advanced leukemia relapsing after an allogeneic progenitor cell transplant. Myelosuppression was acceptable if stem cells were administered 5 days after the last dose of decitabine. Future studies examining the cellular events associated with decitabine therapy, and combining decitabine with other chemotherapeutic agents as preparative regimens for allogeneic transplant, or as salvage therapy for relapse after allogeneic transplant are warranted.
